Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Inclusion Criteria: * Is male or female and 18 to 65 years of age, inclusive, at screening * Has a history of T2DM and a stable dose of metformin * Has HbA1c levels at screening between 7% and 10% Exclusion Criteria: * Is pregnant or lactating * Has type 1 diabetes * Has a significant change in body weight in the 3 months before screening * Has a fasting plasma glucose level greater than 240 mg/dL (13.3 mmol/L) at screening * Has an estimated glomerular filtration rate rate \<75 mL/min/1.73 m2 or has ≥75 mL/min/1.73 m2 \<estimated glomerular filtration rate \<90 mL/min/1.73 m2 with a urine albumin to urine creatinine ratio \>30 mg/g. * Has alanine aminotransferase or aspartate aminotransferase values \>2.0 × upper limit of normal or total bilirubin \>1.5 × upper limit of normal unless the subject has a known history of Gilbert's syndrome * Has fasting serum triglycerides \>400 mg/dL (\>4.52 mmol/L) or \>250 mg/dL (\>2.85 mmol/L) if not on stable lipid-lowering therapy for at least 4 weeks prior to screening, or has calcitonin ≥50 ng/L. Subjects with a history of Fredrickson's Type I, IV or V hyperlipidemia will be excluded. * Has any history of GI intolerance, chronic diarrhea, inflammatory bowel disease, partial bypass or gastric banding * Has any acute illness within 5 days before first study drug administration * Has elevated amylase, ongoing cholelithiasis, cholecystitis at screening, or history of pancreatitis * Is a heavy tobacco user(more than 10 cigarettes a day) * Is a heavy alcohol user * Has a positive screen for drugs of abuse